What Was Behind CervoMed’s Lewy Body Disappointment?

Shares in the CNS disease-focused biotech crashed by nearly 80% after its lead product, neflamapimodin, failed in a Phase IIb study in Lewy body dementia. Investors are pondering what went wrong.

Parkinson's disease. 3D illustration showing neurons containing Lewy bodies small red spheres which are deposits of proteins accumulated in brain cells that cause their progressive degeneration - Illustration
Lewy Bodies • Source: Shutterstock

More from Clinical Trials

More from Therapy Areas